A homogeneous cell-based assay for measurement of endogenous paraoxonase 1 activity

Analytical Biochemistry

Volumn 400, Issue 1, 2010, Pages 1-9

  Ahmad, Syed ^a   Carter, Jade J ^a   Scott, John E ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

Aspirin; DEPFMU; PON1; Quercetin; Simvastatin

Indexed keywords

CYTOLOGY; DETOXIFICATION; DIMETHYL SULFOXIDE; DRUG PRODUCTS; FLAVONOIDS; PHENOLS; SODIUM CHLORIDE;

ASPIRIN; DEPFMU; PON1; QUERCETIN; SIMVASTATIN;

CELLS;

7 DIETHYLPHOSPHO 6,8 DIFLUORO 4 METHYLUMBELLIFERYL; ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; CARBOSTYRIL; DIMETHYL SULFOXIDE; QUERCETIN; QUINOLINOL DERIVATIVE; REAGENT; SIMVASTATIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL COUNT; CELL LINE; CELL LINE HUH7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FALSE POSITIVE RESULT; FLUORESCENCE; HUMAN; HUMAN CELL; MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALINITY; SERUM; TEMPERATURE;

EID: 77649181274     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.01.023     Document Type: Article

References (38)

1. van Himbergen T.M., van Tits L.J., Roest M., and Stalenhoef A.F. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth. J. Med. 64 (2006) 34-38
2. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat. Genet. 14 (1996) 334-336
3. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol. 59 (2004) 479-484
4. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
5. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., and Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281 (2006) 7657-7665
6. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., and Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101 (2000) 2510-2517
7. Florentin M., Liberopoulos E.N., Wierzbicki A.S., and Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 23 (2008) 370-378
8. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., and Hegele R.A. Paraoxonase: biochemistry, genetics, and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7 (1996) 69-76
9. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., and James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277 (2002) 4301-4308
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
11. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., and Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 (2004) 412-419
12. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
13. Mackness B., Quarck R., Verreth W., Mackness M., and Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1545-1550
14. Oda M.N., Bielicki J.K., Ho T.T., Berger T., Rubin E.M., and Forte T.M. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290 (2002) 921-927
15. She Z.G., Zheng W., Wei Y.S., Chen H.Z., Wang A.B., Li H.L., Liu G., Zhang R., Liu J.J., Stallcup W.B., Zhou Z., Liu D.P., and Liang C.C. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ. Res. 104 (2009) 1160-1168
16. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., and Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
17. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., and Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
18. Arii K., Suehiro T., Ota K., Ikeda Y., Kumon Y., Osaki F., Inoue M., Inada S., Ogami N., Takata H., Hashimoto K., and Terada Y. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 202 (2009) 439-445
19. Deakin S., Leviev I., Guernier S., and James R.W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2083-2089
20. Ota K., Suehiro T., Arii K., Ikeda Y., Kumon Y., Osaki F., and Hashimoto K. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 54 (2005) 142-150
21. Muacevic-Katanec D., Bradamante V., Poljicanin T., Reiner Z., Babic Z., Simeon-Rudolf V., and Katanec D. Clinical study on the effect of simvastatin on paraoxonase activity. Arzneimittelforschung 57 (2007) 647-653
22. Gouedard C., Barouki R., and Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol. 24 (2004) 5209-5222
23. Gouedard C., Barouki R., and Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2378-2383
24. Gong M., Garige M., Varatharajalu R., Marmillot P., Gottipatti C., Leckey L.C., and Lakshman R.M. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem. Biophys. Res. Commun. 379 (2009) 1001-1004
25. Curtin B.F., Seetharam K.I., Dhoieam P., Gordon R.K., Doctor B.P., and Nambiar M.P. Resveratrol induces catalytic bioscavenger paraoxonase 1 expression and protects against chemical warfare nerve agent toxicity in human cell lines. J. Cell. Biochem. 103 (2008) 1524-1535
26. Jaichander P., Selvarajan K., Garelnabi M., and Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J. Lipid Res. 49 (2008) 2142-2148
27. Kumon Y., Nakauchi Y., Suehiro T., Shiinoki T., Tanimoto N., Inoue M., Nakamura T., Hashimoto K., and Sipe J.D. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 9 (2002) 160-164
28. Kumon Y., Suehiro T., Ikeda Y., and Hashimoto K. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1β and tumor necrosis factor-α, but is upregulated by interleukin-6. Life Sci. 73 (2003) 2807-2815
29. Van Lenten B.J., Wagner A.C., Navab M., and Fogelman A.M. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J. Biol. Chem. 276 (2001) 1923-1929
30. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
31. Khersonsky O., and Tawfik D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. ChemBioChem 7 (2006) 49-53
32. Han C.Y., Chiba T., Campbell J.S., Fausto N., Chaisson M., Orasanu G., Plutzky J., and Chait A. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1806-1813
33. Osaki F., Ikeda Y., Suehiro T., Ota K., Tsuzura S., Arii K., Kumon Y., and Hashimoto K. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 176 (2004) 279-287
34. Soukharev S., and Hammond D.J. A fluorogenic substrate for detection of organophosphatase activity. Anal. Biochem. 327 (2004) 140-148
35. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., and Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA 101 (2004) 482-487
36. Beltowski J., Wojcicka G., and Marciniak A. Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. Acta Biochim. Pol. 49 (2002) 927-936
37. Eckerson H.W., Romson J., Wyte C., and La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am. J. Hum. Genet. 35 (1983) 214-227
38. Zhang J., Thomas D., Chung Y., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-74